Celularity (CELU) Profit After Tax (2019 - 2025)
Celularity (CELU) posted quarterly Profit After Tax of $6.0 million for Q4 2025, up 120.98% year-over-year from $2.7 million in Q4 2024, and up 146.87% quarter-over-quarter from -$12.9 million in Q3 2025.
Celularity (CELU) Profit After Tax (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Profit After Tax for 7 consecutive years, with $6.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax rose 120.98% year-over-year to $6.0 million; the TTM figure through Dec 2025 stood at -$51.1 million (up 30.35% YoY), while the FY2025 annual figure was -$61.3 million, down 5.9% from the prior year.
- Profit After Tax improved to $6.0 million in Q4 2025 per CELU's latest filing, from -$12.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at $49.9 million in Q3 2021 and bottomed at -$93.9 million in Q3 2023.
- Historically, Profit After Tax has averaged -$18.7 million across 5 years, with a median of -$16.1 million in 2024.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 506.71% — and 2023, when it slumped 1562.7%.
- Celularity's Profit After Tax stood at -$6.0 million in 2021, then jumped by 506.71% to $24.4 million in 2022, then plunged by 44.54% to $13.6 million in 2023, then slumped by 312.57% to -$28.8 million in 2024, then soared by 120.98% to $6.0 million in 2025.
- Business Quant data shows CELU's Profit After Tax at $6.0 million in Q4 2025, -$12.9 million in Q3 2025, and -$24.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | -24.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.05 Mn |
| Sep 30, 2025 | -12.90 Mn |
| Jun 30, 2025 | -24.52 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -28.81 Mn |
| Sep 30, 2024 | -16.10 Mn |
| Jun 30, 2024 | -6.49 Mn |
| Mar 31, 2024 | -22.01 Mn |
| Dec 31, 2023 | 13.56 Mn |
| Sep 30, 2023 | -93.88 Mn |
| Jun 30, 2023 | -48.22 Mn |
| Mar 31, 2023 | 2.66 Mn |
| Dec 31, 2022 | 24.44 Mn |
| Sep 30, 2022 | -5.65 Mn |
| Mar 31, 2022 | -62.87 Mn |
| Dec 31, 2021 | -6.01 Mn |
| Sep 30, 2021 | 49.94 Mn |
| Jun 30, 2021 | -60.61 Mn |
| Mar 31, 2021 | -44.40 Mn |
| Dec 31, 2020 | 3.91 Mn |